{"id":5222,"date":"2021-11-21T11:36:34","date_gmt":"2021-11-21T10:36:34","guid":{"rendered":"https:\/\/nanexa.com\/?page_id=5222"},"modified":"2022-05-19T11:51:45","modified_gmt":"2022-05-19T09:51:45","slug":"nex-20","status":"publish","type":"page","link":"https:\/\/nanexa.com\/sv\/nex-20\/","title":{"rendered":"NEX-20"},"content":{"rendered":"\n
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\n\n

nex-20<\/span> f\u00f6r behandling
av multipelt myelom
<\/span><\/h1>\n\n\n\t\t\t<\/div>\n\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
  1. Vad \u00e4r multipelt myelom?<\/a><\/li>
  2. NEX-20: Kontrollerad fris\u00e4ttning ger b\u00e4ttre efterlevnad<\/a><\/li>\t\t\t\t<\/ol>\t\t\t<\/div>\n\t\t<\/div>\n\t\t
    \n\t\t\t\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n
    <\/div>

    vad \u00e4r<\/p><\/div>

    \n\n

    VAD \u00c4R MultipELT myelom<\/span><\/h2>\n\n\n\n

    Multipelt myelom \u00e4r en hematologisk cancersjukdom som fr\u00e4mst upptr\u00e4der i benm\u00e4rgen. De vanligaste symptomen \u00e4r sm\u00e4rtor i ryggen eller br\u00f6stkorgen, tr\u00f6tthet, f\u00f6rs\u00e4mrat immunf\u00f6rsvar, f\u00f6rvirring, njurskador.<\/p>\n\n\n\n

    Multipelt myelom \u00e4r en \u00e5terkommande cancersjukdom med flera stadier, d\u00e4r behandlingen \u00e4r b\u00e5de l\u00e5ng och kr\u00e4vande, men d\u00e4r flera framsteg har gjorts de senaste decennierna. \u00d6verlevnaden har d\u00e4rmed \u00f6kat och \u00e4r idag ca 55% efter 5 \u00e5r (1)<\/sup>.<\/p>\n\n\n\n

    Det g\u00e5r \u00e4nnu inte att bota myelom men behandlingsm\u00f6jligheterna har f\u00f6rb\u00e4ttrats drastiskt p\u00e5 senare \u00e5r. Genom en kombination av l\u00e4kemedelsbehandling och stamcellstransplantation n\u00e5r m\u00e5nga patienter idag en stabil remission som varar i flera \u00e5r.<\/p>\n\n\n\n

    \u00c4ven om f\u00f6rsta linjens behandlingar fungerar kan de utl\u00f6sa allvarliga och besv\u00e4rliga biverkningar som g\u00f6r det sv\u00e5rt f\u00f6r patienterna att efterleva sin livr\u00e4ddande behandlingsregim.<\/p>\n\n\n\n

    \n
    \n

    F\u00d6REKOMST<\/span><\/strong><\/p>\n\n\n\n

    Sjukdomen drabbar huvudsakligen \u00e4ldre och \u00e4r vanligare hos m\u00e4n, med en genomsnitts\u00e5lder av 69 \u00e5r vid diagnos. Globalt s\u00e5 insjuknar ca 140 000 m\u00e4nniskor (2)<\/sup>. I och med att \u00f6verlevnaden har f\u00f6rl\u00e4ngts s\u00e5 \u00e4r det allt fler m\u00e4nniskor som lever med multipelt myelom.  <\/p>\n\n\n\n

    \u00c5r 2019 uppskattades cirka 160 000 m\u00e4nniskor leva med multipelt myelom i USA (1)<\/sup>.<\/p>\n<\/div>\n\n\n\n

    \n
    \n\t
    \n\t\t\t\t\t

    Antal nyinsjuknande i
    Multipelt Myelom globalt<\/p>\n\t\t\t\t\t<\/div>\n\t\t

    \n\t\t\t\n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \u00c5R<\/div>\n\t\t\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

    Afrika<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t

    \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t\t\t\t

    Europa<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t

    \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t\t\t\t

    Nordamerika<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t\t
    \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t\t\t\t

    Asien<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t

    \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t\t\t\t

    Latinamerika och V\u00e4stindien<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t

    \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t\t\t\t

    Oceanien<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<\/div>\n<\/div>\n\n\n\n

    DYNAMISKT BEHANDLINGSLANDSKAP<\/span><\/strong><\/p>\n\n\n\n

    Sjukdomsm\u00f6nstret vid multipelt myelom \u00e4r en serie \u00e5terfall d\u00e4r patienten genomg\u00e5r ett antal olika behandlingslinjer. Perioder av tillfrisknande f\u00f6ljs av \u00e5terfall i takt med att cancercellerna blir resistenta mot behandlingen. D\u00e4rf\u00f6r beh\u00f6vs nya l\u00e4kemedel. \u00d6verlevnaden hos patienter med multipelt myelom har p\u00e5 senare \u00e5r f\u00f6rl\u00e4ngts tack vare nya l\u00e4kemedel och nya kombinationer av befintliga l\u00e4kemedel. Hit h\u00f6r bland annat immunmodulerande l\u00e4kemedel i IMiD-kategorin, d\u00e4r lenalidomid (produktnamn: Revlimid\u00ae) \u00e4r en s\u00e5 kallad basterapi i m\u00e5nga av kombinationerna.<\/p>\n\n\n\n

    LENALIDOMID: BASTERAPI MED D\u00c5LIG EFTERLEVNAD<\/span><\/h3>\n\n\n
    <\/div>
    \n\n

    Lenalidomid \u00e4r en immunmodulerande substans inriktad s\u00e5v\u00e4l p\u00e5 cancercellerna som p\u00e5 den omgivande mikromilj\u00f6n (3)<\/sup>. Patienterna intar lenalidomid i form av en oral kapsel (25 mg) en g\u00e5ng om dagen under 21 dagar i str\u00e4ck under en behandlingscykel om 28 dagar. Det \u00e4r ingen tvekan om att behandling med lenalidomid ger \u00f6kad \u00f6verlevnad\u00a0(4)<\/sup>\u00a0men ocks\u00e5 biverkningar som diarr\u00e9, tr\u00f6tthet och illam\u00e5ende \u00e4r vanliga. Biverkningarna kan f\u00f6r vissa patienter bli s\u00e5 st\u00f6rande och obehagliga att de avviker fr\u00e5n sin livr\u00e4ddande behandlingsregim.<\/p>\n\n\n\n\n

    \n \n\n

    (1)<\/strong>\u00a0NIH, SEER, Multiple Myeloma
    (2)<\/strong>\u00a0Datamonitor Multiple Myeloma Disease Analysis Feb 2022
    (3)<\/strong> A review of the history, properties, and use of the immunomodulatory compound lenalidomide Zeldis et al. Ann N Y Acad Sci. 2011 Mar;1222:76-82
    (4)<\/strong> Multiple Myeloma Research Foundation<\/a><\/p>\n\n\n<\/div>\n\n<\/div>\n<\/div><\/section>\n\n

    <\/div>

    kontrollerad fris\u00e4ttning<\/p><\/div>

    \n\n

    KONTROLLERAD FRIS\u00c4TTNING GER b\u00e4ttre efterlevnad<\/span> <\/h2>\n\n\n\n\n
    \n\t\t
    \n\t\t
    \n\t\t\t\n\t\t\t

    En injektion i m\u00e5naden i st\u00e4llet f\u00f6r en kapsel om dagen i 21-28 dagar<\/span><\/h3>\n\t\t\t\n\t\t<\/div>\n\t\t
    \n\t\t\t\n\n

    NEX-20 kommer att kunna ers\u00e4tta en daglig oral dos lenalidomid under 21-28 dagar med en enda injektion per m\u00e5nad, som ges p\u00e5 kliniken.<\/h3>\n\n\n\n

    MER \u00c4N VAR TREDJE PATIENT MED MULTIPELT MYELOM HAR D\u00c5LIG EFTERLEVNAD<\/strong><\/strong>
    En studie av 793 patienter visade nyligen att 38 procent, det vill s\u00e4ga mer \u00e4n en tredjedel, ans\u00e5gs ha bristf\u00e4llig efterlevnad avseende lenalidomid. I studien anv\u00e4ndes innehav av l\u00e4kemedlet som proxyvariabel f\u00f6r efterlevnad. (5)<\/sup><\/p>\n\n\n\t\t<\/div>\n\t<\/div>\n\t\n<\/div>\n\n\n\n

    Mer \u00e4n var tredje \u00e4ldre patient med nydiagnostiserat multipelt myelom anses ha bristf\u00e4llig efterlevnad avseende lenalidomid. Det visar p\u00e5 behovet av att f\u00f6rst\u00e5 olika faktorer b\u00e4ttre och av att utveckla strategier f\u00f6r att st\u00e4rka efterlevnaden hos denna patientgrupp.<\/p>LYMFOM, MYELOM OCH LEUKEMI I KLINISK MILJ\u00d6<\/cite><\/blockquote>\n\n\n\n

    <\/p>\n\n\n\n

    Dagens orala administrering g\u00f6r det ganska l\u00e4tt f\u00f6r patienter som tycker att biverkningarna \u00e4r alltf\u00f6r besv\u00e4rliga att helt enkelt sluta ta den medicin de beh\u00f6ver. Om lenalidomid injicerades p\u00e5 klinik en g\u00e5ng i m\u00e5naden skulle det f\u00f6rb\u00e4ttra f\u00f6rskrivning och efterlevnad avsev\u00e4rt.<\/p>\n\n\n\n

    <\/p>\n\n\n\n

    Detta g\u00f6r l\u00e4kemedlen billigare f\u00f6r patienterna och i USA f\u00e5r sjukv\u00e5rdsleverant\u00f6rerna \u00e4ven ett annat incitament, n\u00e4mligen att injektioner p\u00e5 kliniken genererar kontinuerlig ers\u00e4ttning, till skillnad fr\u00e5n receptbelagda tabletter.<\/p>US KEY OPINION LEADER, TEXAS<\/cite><\/blockquote>\n\n\n\n\n

    \n \n\n

    (5)<\/strong> Clin Lymphoma Myeloma Leuk. 2020;20(2):98-104<\/p>\n\n\n<\/div>\n\n<\/div><\/section>","protected":false},"excerpt":{"rendered":"

    nex-20 f\u00f6r behandling
    av multipelt myelom<\/p>\n

      \n
    1. Vad \u00e4r multipelt myelom?<\/a><\/li>\n
    2. NEX-20: Kontrollerad fris\u00e4ttning ger b\u00e4ttre efterlevnad<\/a><\/li>\n<\/ol>\n

      \t\t\t<\/p>\n

      vad \u00e4r<\/p>\n

      VAD \u00c4R MultipELT myelom<\/p>\n

      Multipelt myelom \u00e4r en hematologisk cancersjukdom som fr\u00e4mst upptr\u00e4der i benm\u00e4rgen.<\/p>\n

      L\u00e4s mer<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-5222","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nNEX-20 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/nex-20\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NEX-20 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"nex-20 f\u00f6r behandling av multipelt myelom Vad \u00e4r multipelt myelom?NEX-20: Kontrollerad fris\u00e4ttning ger b\u00e4ttre efterlevnad vad \u00e4r VAD \u00c4R MultipELT myelom Multipelt myelom \u00e4r en hematologisk cancersjukdom som fr\u00e4mst upptr\u00e4der i benm\u00e4rgen.L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/nex-20\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-19T09:51:45+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nex-20\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/nex-20\\\/\",\"name\":\"NEX-20 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2021-11-21T10:36:34+00:00\",\"dateModified\":\"2022-05-19T09:51:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/nex-20\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/nex-20\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nex-20\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NEX-20\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NEX-20 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/nex-20\/","og_locale":"sv_SE","og_type":"article","og_title":"NEX-20 - Nanexa AB","og_description":"nex-20 f\u00f6r behandling av multipelt myelom Vad \u00e4r multipelt myelom?NEX-20: Kontrollerad fris\u00e4ttning ger b\u00e4ttre efterlevnad vad \u00e4r VAD \u00c4R MultipELT myelom Multipelt myelom \u00e4r en hematologisk cancersjukdom som fr\u00e4mst upptr\u00e4der i benm\u00e4rgen.L\u00e4s mer","og_url":"https:\/\/nanexa.com\/nex-20\/","og_site_name":"Nanexa AB","article_modified_time":"2022-05-19T09:51:45+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/nex-20\/","url":"https:\/\/nanexa.com\/nex-20\/","name":"NEX-20 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2021-11-21T10:36:34+00:00","dateModified":"2022-05-19T09:51:45+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/nex-20\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/nex-20\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/nex-20\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"NEX-20"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/pages\/5222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/comments?post=5222"}],"version-history":[{"count":229,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/pages\/5222\/revisions"}],"predecessor-version":[{"id":6379,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/pages\/5222\/revisions\/6379"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=5222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}